Sandbox:Balanitis xerotica obliterans: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
Line 188: Line 188:
Good hygiene which include retracting the foreskin regularly and gentle cleansing of entire glans, preputial sac, and foreskin were found effective in treating the diseases.<ref name="pmid248285533">{{cite journal| author=Edwards SK, Bunker CB, Ziller F, van der Meijden WI| title=2013 European guideline for the management of balanoposthitis. | journal=Int J STD AIDS | year= 2014 | volume= 25 | issue= 9 | pages= 615-26 | pmid=24828553 | doi=10.1177/0956462414533099 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24828553  }}</ref>
Good hygiene which include retracting the foreskin regularly and gentle cleansing of entire glans, preputial sac, and foreskin were found effective in treating the diseases.<ref name="pmid248285533">{{cite journal| author=Edwards SK, Bunker CB, Ziller F, van der Meijden WI| title=2013 European guideline for the management of balanoposthitis. | journal=Int J STD AIDS | year= 2014 | volume= 25 | issue= 9 | pages= 615-26 | pmid=24828553 | doi=10.1177/0956462414533099 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24828553  }}</ref>
===Medical Therapy===
===Medical Therapy===
Medical therapy for BXO include:<ref name="pmid220851202">{{cite journal| author=Clouston D, Hall A, Lawrentschuk N| title=Penile lichen sclerosus (balanitis xerotica obliterans). | journal=BJU Int | year= 2011 | volume= 108 Suppl 2 | issue=  | pages= 14-9 | pmid=22085120 | doi=10.1111/j.1464-410X.2011.10699.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22085120  }}</ref>
{| class="wikitable"
{| class="wikitable"
! colspan="3" |Various medical managements for Zoons balanitis
! colspan="3" |Various medical managements for BXO
!
!
|-
|-
Line 197: Line 198:
!
!
|-
|-
| rowspan="2" |Topical steroids
|Topical steroids
|Saline compresses containing 1% hydrocortisone/0.02% betamethason+/-17-valerate/0.05% betamethasone dipropionate
|Betamethasone diproprionate 0.05% or or clobetasol proprionate 0.05% cream or ointment once or twice daily
After 6–8 weeks, reduce the application of the topical steroid to every second day
 
After 12–16 weeks to assess response to treatment(mometasone aceponate 0.1% cream can be substituted if there is a good response)
 
No improvement by 6 months, then use of the potent topical steroid should be abandoned.
 
|3 out of 6 patients responded
|3 out of 6 patients responded
|
|
|-
|-
|Oxytetracycline 3%, nystatin 100,00(units/g), and clobetasone butyrate 0.05% applied until complete resolution was observed
| rowspan="2" |Topical calineurin inhibitors
|All patients responded, but 3 out of 10 patients had recurrences
|
|-
|Topical calineurin
|Tacrolimus ointment 0.1% twice daily
|Tacrolimus ointment 0.1% twice daily
|Complete remission after 4 weeks of treatment was observed in 9 patients , with no relapse observed after 3 months of follow up
| rowspan="2" |Shouldn't be used as first-line therapy
|
|
|-
|-
|Topical Pimecrolimus
|Pimecrolimus cream 1% twice daily
|Pimecrolimus cream 1% twice daily
|Improvement is observed after 2 months of treatment with no relapse observed
|
|
|-
|-
| rowspan="2" |Topical Imiquimod
| rowspan="2" |Tricyclic antidepressant or gabapentin.
|5% imiquimod cream, 3 times a week for 4 months with multiple periods without treatment
| colspan="2" rowspan="2" |Can be used in cases when BOX is associated with penile dysaesthesia.
| rowspan="2" |Complete resolution can be found after 4-12 weeks of treatment, with no cases of relapse observed
|
|
|-
|-
|5% imiquimod cream, 3 times a week for 12 months without any interruption
|
|
|}
|}

Revision as of 16:20, 23 January 2017


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Vishal Devarkonda, M.B.B.S[2]

Synonyms and keywords:BXO, Penile lichen sclerosus

Overview

Balanitis xerotica obliterans (BXO) is a dermatological (skin) condition affecting the male genitalia. It was first described by Stuhmer in 1928, though earlier reports describe what may have been the same condition.[1] BXO commonly occurs on the foreskin and glans penis.[2] Atrophic white patches appear on the affected area,[3] and commonly, a whitish ring of indurated (hardened) tissue usually forms near the tip that may prevent retraction.[2]

Historical Perspective

Classification

There is no established classification system for BXO.

Pathophysiology

The exact etiology of BXO is unknown, but multiple factors are considered to play an important in the development of BXO.

Factors associated with pathogenesis of BXO
Uncircumcised Penis Accumulation of secretions and epithelial debris between the foreskin and coronal sulcus leads to chronic irritation, sublincal trauma. [1]
Autoimmune diseases Patients with BXO, were found to have an other associated autoimmune conditions, which include: diabetes mellitus, vitiligo, alopecia aerata.[2]

Some studies have showned association between BXO and HLA DQ7 with DR11 and DR12.[3]

Infections Human papillomavirus (HPV) Several studies have implicated human papillomavirus as a causative agent in pathogenesis of BXO. HPV 16, 18, 33 and 51 have been found to associated with BXO.

Recent studies reported lack of clincal correlation of BXO and HPV, has they both have unrelated transcriptosome.

Several studies have reported association of various infectious organisms with development of Balanitis xerotica obliterans, which include:
  • Borrelia burgdoferi[4]
  • HCV[5]
  • Epstein-Barr virus[6]
Genetics Several studies have proposed genetic association and lichen sclerosis.

In females, 12% of patients were found to have a family history of lichen sclerosis,.

In males, there is no evidence familial predisposition.

Envirnomental factors

BXO is known to demonstrate koebner phenomenon.[7]

Trauma, old scars, skin grafts, sunburn and radiation were found to be associated with BXO.[7]

Some studies have proposed that post-micturation dribbling or microincontinence plays a central role in development of BXO.[8]

Histopathology

Histopatholgy findings found in BXO include:[9]

Early stage of BXO

  • Moderately heavy lymphocytic infiltrate in found in basal epidermis and superficial dermis in early stages of the lesion.

Late stages of BXO

  • Epidermis becomes atrophic with surface hyperkeratosis, thickened basement membrane
  • Broad zone of subepidermal oedema with homogenization of collagen, which becomes more sclerotic over time.
  • In few cases, epidermis is detached from dermis resulting in formation of haemorrhagic bullae.
  • <section></section>

Causes

The etiology of BXO is uncertain. However, some possibilities have been suggested.

Some studies have shown that patients with BXO also show signs of suffering from autoimmune disorders.[10][11][12] However, this finding is not repeated in every study.[11]

Infection from "human papilloma virus (serotype 16 in particular), spirochetes and atypical mycobacteria" has also been suggested as a cause.[13] Additional suggestions include "pemphigus vulgaris and chronic nonspecific bacterial balanitis".[14]

Relationship to phimosis

BXO is a common cause of pathological phimosis.

Kiss et al. report that 40% of boys with phimosis suffered from BXO.[15] Shankar and Rickwood reported BXO in 84% of phimosis patients.[16] Evans reported BXO in 10.5% of phimosis patients.[17] Clemmensen et al. reported BXO in 14.2% of phimosis patients.[18] Bale reported that BXO was found in 19% of circumcisions performed for diseases of the prepuce and penis.[19] Mattioli observed BXO in 60% of patients with acquired phimosis and 30% of patients with congenital phimosis.[20] Rickwood reported BXO in 20 of 21 patients circumcised for pathological phimosis.[21]

Relationship to lichen sclerosus

Many researchers regard BXO as lichen sclerosus et atrophicus (LSA) of the penis, LSA is also known as lichen sclerosus (LS). Lately BXO was coded as part of LSA by Medical literature search tool Medline.[22][23][24] However, Mallon et al. suggest that BXO "may be a consequence of other fibrosing dermatoses, such as lichen planus and cicatricial pemphigoid."[25] When occurring on the male genitals, the term 'BXO' is traditionally used.

Epidemiology and Demographics

The true prevalence of BXO is controversial and unclear. One study calculated a rate of 0.6% of boys affected by their 15th birthday.[16] Another reported a rate of 0.07%.[13] However, a review noted that "with a high degree of suspicion and histologic examination, the condition will prove to be much more frequent than one generally believes."[26] Another suggested that "more cases would be diagnosed during infancy if all dried foreskin were examined systematically."[27] Another remarked that the condition "may be misdiagnosed or ignored in the young boy."[28] Yet another commented that "its true incidence is not appreciated because most cases are cured by circumcision, and unfortunately many surgeons still fail to send their circumcision specimens for histology."[29] Another remarked that the "extent of asymptomatic disease in this series would suggest the true prevalence of LS in men might be much higher than published work suggests."[30]

According to some authors, the disease most frequently affects middle-aged men. However, a large study reported that the age distribution was similar from 2 to 90 years of age, except for men in their twenties, who were at twice the risk.[13] The same study found that black and Hispanic men had approximately twice the risk of white men. The authors suggested possible reasons for this, including access to health care, differences in neonatal circumcision rates, and climate differences.

Mallon et al. found that BXO was related to circumcision status. Adjusting for age, lack of circumcision was associated with an odds ratio of 53.55. The finding was statistically significant.[25] However, BXO has also been noted to occur after late circumcision, especially when performed for phimosis.[25][13]

Screening

There is no established screening guidelines for BXO.

Natural History, Complications, and Prognosis

Natural history

If left untreated, there is risk for malignant transformation.[31]

Complications

Complications of Zoon balanitis include:

  • Phimosis
  • Paraphimosis

Prognosis

BXO is chronic and often progressive. Please see the following section on treatment.

The condition may cause pain, irritation, and disturbance of sexual function.[14]

In later stages, a meatal stricture may occur, causing urinary retention. This may result in bladder or kidney damage.

The coronal sulcus and frenulum may be destroyed.

Phimosis or paraphimosis may occur.

Several studies indicate that BXO may play a pre-cancerous role,[32][33][34][35][36] resulting in squamous cell carcinoma of the penis, a form of penile cancer.

Prognosis is good with treatment.[37]

Diagnosis

Neuhaus and Skidmore report that "Tzanck smear and cutaneous biopsy, along with a rapid protein reagin test, will provide a definitive diagnosis."[38]

Depasquale et al. note that many surgeons do not send circumcision specimens for histology. They caution that this practice "is becoming medicolegally indefensible in a litigation-conscious society, where the clinical sequelae of BXO are often misinterpreted by the patient as surgical errors."[29]

History and symptoms

Patients with Zoon balanitits could be asymptomatic or present with:[39]

  • Itching (pruritus) of the genitalia.
  • Discomfort in urination(dysuria)
  • Pain in the gential region
  • blood stain discharge
  • Difficult or painful sexual intercourse

Physical examination

Physical examination findings include:[40][41]

  • Well circumscribed single or multiple, orange-red in colour with a characteristic glazed appearance and multiple pinpoint redder spots-"cayenne pepper spots"(please click here to view the image) most commonly involving the glans penis, but inner surface of prepuce and coronal sulcus may be involved.
  • Though uncommon, lesions of Zoon balanitis can involve other sites which include labia minora in females, oral mucosa, conjunctiva, urethra, cheeks, and epiglottis have been described in literature.[42]
Clinical criteria in diagnosing Zoon balanitis [41]
Shiny, erythematous patches on the glans, prepuce, or both
Lesion present for > 3months
Absence of lesion suggestive of Lichen planus, psoriasis elsewhere on the body
Poor response to topical therapies
Absence of concurrent infections which are ruled out after performing tzanck, potassium hydroxide, gram stain, and VDRL test.

Laboratory findings

Reflectance confocal microscopy A nucleated honeycomb pattern and vermicular vessels is a clue for benign inflammatory genital skin disease[43]
Dermoscopy Focal/diffuse orange-yellowish structure, less areas representing hemosiderin deposition, curved vessels due to epidermal thinning helps in distinguishing ZB from carcinoma in situ.[44]

Treatment

Therapy focuses on prevention of disease progression.[30]

Shelley reported some success with long-term antibiotic therapy. However, relapses were seen upon stopping treatment.[31]

Some success has been reported with topical steroids,[32] when scarring is minimal,[33] though some have found this ineffectual.[34]

Moderate therapeutic results have been reported using etretinate.[35]

Some success has been reported in the use of carbon dioxide laser therapy.[36][37]

Many authors report that circumcision is the treatment of choice,[9][2][38] with modifications if necessary.[39] Pasieczny suggests testosterone ointment, however.[40]

Glansectomy may be required.[9]

Currently, topical steriods are the most commonly used and most effective medication for the treatment of the adverse skin changes associated with BXO. Patients with urethral stricture disease associated with BXO are generally best managed with surgery to relieve the obstruction. Although urethral dilation is a treatment option, this treatment generally offers only temporary relief of the blockage and a complication of dilations can be stricture progression. The best treatment of urethral stricture treatment options are extended meatotomy (an open incision of the urethra) for short strictures and staged tissue transfer urethroplasty, a surgery to reconstruct the urethra using grafts such as buccal mucosa from inside the cheek.

General measures

Good hygiene which include retracting the foreskin regularly and gentle cleansing of entire glans, preputial sac, and foreskin were found effective in treating the diseases.[45]

Medical Therapy

Medical therapy for BXO include:[46]

Various medical managements for BXO
Drug dosage Effectiveness
Topical steroids Betamethasone diproprionate 0.05% or or clobetasol proprionate 0.05% cream or ointment once or twice daily

After 6–8 weeks, reduce the application of the topical steroid to every second day

After 12–16 weeks to assess response to treatment(mometasone aceponate 0.1% cream can be substituted if there is a good response)

No improvement by 6 months, then use of the potent topical steroid should be abandoned.

3 out of 6 patients responded
Topical calineurin inhibitors Tacrolimus ointment 0.1% twice daily Shouldn't be used as first-line therapy
Pimecrolimus cream 1% twice daily
Tricyclic antidepressant or gabapentin. Can be used in cases when BOX is associated with penile dysaesthesia.

Surgery

Prevention

There is no known means of preventing BXO. However, one study reports that the data "suggest that circumcision prevents or protects against common infective penile dermatoses."[25]

Primary Prevention

Circumcision in males can help in reducing risk of having ZB.[47]

Secondary prevention

There is no secondary prevention measures.

References

  1. ↑ Schempp C, Bocklage H, Lange R, Kölmel HW, Orfanos CE, Gollnick H (1993). "Further evidence for Borrelia burgdorferi infection in morphea and lichen sclerosus et atrophicus confirmed by DNA amplification". J Invest Dermatol. 100 (5): 717–20. PMID 8491994.
  2. ↑ Meffert JJ, Davis BM, Grimwood RE (1995). "Lichen sclerosus". J Am Acad Dermatol. 32 (3): 393–416, quiz 417-8. PMID 7868709.
  3. ↑ Azurdia RM, Luzzi GA, Byren I, Welsh K, Wojnarowska F, Marren P; et al. (1999). "Lichen sclerosus in adult men: a study of HLA associations and susceptibility to autoimmune disease". Br J Dermatol. 140 (1): 79–83. PMID 10215772.
  4. ↑ Fujiwara H, Fujiwara K, Hashimoto K, Mehregan AH, Schaumburg-Lever G, Lange R; et al. (1997). "Detection of Borrelia burgdorferi DNA (B garinii or B afzelii) in morphea and lichen sclerosus et atrophicus tissues of German and Japanese but not of US patients". Arch Dermatol. 133 (1): 41–4. PMID 9006371.
  5. ↑ Boulinguez S, Bernard P, Lacour JP, Nicot T, Bedane C, Ortonne JP; et al. (1997). "Bullous lichen sclerosus with chronic hepatitis C virus infection". Br J Dermatol. 137 (3): 474–5. PMID 9349358.
  6. ↑ Aidé S, Lattario FR, Almeida G, do Val IC, da Costa Carvalho M (2010). "Epstein-Barr virus and human papillomavirus infection in vulvar lichen sclerosus". J Low Genit Tract Dis. 14 (4): 319–22. doi:10.1097/LGT.0b013e3181d734f1. PMID 20885159.
  7. ↑ 7.0 7.1 Bjekić M, Šipetić S, Marinković J (2011). "Risk factors for genital lichen sclerosus in men". Br J Dermatol. 164 (2): 325–9. doi:10.1111/j.1365-2133.2010.10091.x. PMID 20973765.
  8. ↑ Bunker CB (2007). "Male genital lichen sclerosus and tacrolimus". Br J Dermatol. 157 (5): 1079–80. doi:10.1111/j.1365-2133.2007.08179.x. PMID 17854373.
  9. ↑ Clouston D, Hall A, Lawrentschuk N (2011). "Penile lichen sclerosus (balanitis xerotica obliterans)". BJU Int. 108 Suppl 2: 14–9. doi:10.1111/j.1464-410X.2011.10699.x. PMID 22085120.
  10. ↑ Azurdia R, Luzzi G, Byren I, Welsh K, Wojnarowska F, Marren P, Edwards A (1999). "Lichen sclerosus in adult men: a study of HLA associations and susceptibility to autoimmune disease". Br J Dermatol. 140 (1): 79–83. PMID 10215772. Unknown parameter |month= ignored (help)
  11. ↑ 11.0 11.1 Meyrick Thomas R, Ridley C, Black M (1983). "The association of lichen sclerosus et atrophicus and autoimmune-related disease in males". Br J Dermatol. 109 (6): 661–4. PMID 6652042. Unknown parameter |month= ignored (help)
  12. ↑ Harrington C, Dunsmore I (1981). "An investigation into the incidence of auto-immune disorders in patients with lichen sclerosus and atrophicus". Br J Dermatol. 104 (5): 563–6. PMID 7236515. Unknown parameter |month= ignored (help)
  13. ↑ 13.0 13.1 13.2 13.3 Kizer W, Prarie T, Morey A (2003). "Balanitis xerotica obliterans: epidemiologic distribution in an equal access health care system". South Med J. 96 (1): 9–11. PMID 12602705. Unknown parameter |month= ignored (help)
  14. ↑ 14.0 14.1 Edwards S. (1996). "Balanitis and balanoposthitis: a review" (Reprint:The CIRP Circumcision Reference Library). Genitourin Med. 72 (3): 155–9.
  15. ↑ Kiss A, Király L, Kutasy B, Merksz M (2005). "High incidence of balanitis xerotica obliterans in boys with phimosis: prospective 10-year study". Pediatr Dermatol. 22 (4): 305–8. PMID 16060864. Unknown parameter |month= ignored (help)
  16. ↑ 16.0 16.1 Shankar K, Rickwood A (1999). "The incidence of phimosis in boys". BJU Int. 84 (1): 101–2. PMID 10444134. Unknown parameter |month= ignored (help)
  17. ↑ Evans D (2000). "Retrospective study of male lichen sclerosus and outcome in Leicester: 1995-9 inclusive: experience of a genitourinary medicine clinic". Sex Transm Infect. 76 (6): 495. PMID 11221136.
  18. ↑ Clemmensen O, Krogh J, Petri M (1988). "The histologic spectrum of prepuces from patients with phimosis". Am J Dermatopathol. 10 (2): 104–8. PMID 3239715. Unknown parameter |month= ignored (help)
  19. ↑ Bale P, Lochhead A, Martin H, Gollow I (1987). "Balanitis xerotica obliterans in children". Pediatr Pathol. 7 (5–6): 617–27. PMID 3449818.
  20. ↑ Mattioli G, Repetto P, Carlini C, Granata C, Gambini C, Jasonni V (2002). "Lichen sclerosus et atrophicus in children with phimosis and hypospadias". Pediatr Surg Int. 18 (4): 273–5. PMID 12021978. Unknown parameter |month= ignored (help)
  21. ↑ Rickwood AMK, Hemalatha V, Batcup G, Spitz L. (1980). "Phimosis in boys" (Reprint:The CIRP Circumcision Reference Library). Brit J Urol. 52: 147–50.
  22. ↑ Finkbeiner A (2003). "Balanitis xerotica obliterans: a form of lichen sclerosus". South Med J. 96 (1): 7–8. PMID 12602704. Unknown parameter |month= ignored (help)
  23. ↑ Laymon CW, Freeman C. (1944). "Relationship of balanitis xerotica obliterans to lichen sclerosus et atrophicus" (Reprint:The CIRP Circumcision Reference Library). Arch Dermat Syph. 49: 57–9.
  24. ↑ Neill S, Tatnall F, Cox N (2002). "Guidelines for the management of lichen sclerosus". Br J Dermatol. 147 (4): 640–9. PMID 12366407. Unknown parameter |month= ignored (help)
  25. ↑ 25.0 25.1 25.2 25.3 Mallon E, Hawkins D, Dinneen M, Francics N, Fearfield L, Newson R, Bunker C (2000). "Circumcision and genital dermatoses". Arch Dermatol. 136 (3): 350–4. PMID 10724196. Unknown parameter |month= ignored (help)
  26. ↑ Das S, Tunuguntla H (2000). "Balanitis xerotica obliterans--a review". World J Urol. 18 (6): 382–7. PMID 11204255. Unknown parameter |month= ignored (help)
  27. ↑ Garat J, Chéchile G, Algaba F, Santaularia J (1986). "Balanitis xerotica obliterans in children". J Urol. 136 (2): 436–7. PMID 3735511. Unknown parameter |month= ignored (help)
  28. ↑ McKay D, Fuqua F, Weinberg A (1975). "Balanitis xerotica obliterans in children". J Urol. 114 (5): 773–5. PMID 1237636. Unknown parameter |month= ignored (help)
  29. ↑ 29.0 29.1 Depasquale I, Park AJ, Bracka A. (2000). "The treatment of balanitis xerotica obliterans" (Reprint:The CIRP Circumcision Reference Library). BJU Int. 86 (4): 459–65. Retrieved 2006-10-01.
  30. ↑ Riddell I, Edwards A, Sherrard J. (2000). "Clinical features of lichen sclerosus in men attending a department of genitourinary medicine". Sex Trans Infect. 76 (4): 311–3. Unknown parameter |month= ignored (help)
  31. ↑ Dayal S, Sahu P (2016). "Zoon balanitis: A comprehensive review". Indian J Sex Transm Dis. 37 (2): 129–138. doi:10.4103/0253-7184.192128. PMC 5111296. PMID 27890945.
  32. ↑ Velazquez E, Cubilla A (2003). "Lichen sclerosus in 68 patients with squamous cell carcinoma of the penis: frequent atypias and correlation with special carcinoma variants suggests a precancerous role". Am J Surg Pathol. 27 (11): 1448–53. PMID 14576478. Unknown parameter |month= ignored (help)
  33. ↑ Cubilla A, Velazquez E, Young R (2004). "Pseudohyperplastic squamous cell carcinoma of the penis associated with lichen sclerosus. An extremely well-differentiated, nonverruciform neoplasm that preferentially affects the foreskin and is frequently misdiagnosed: a report of 10 cases of a distinctive clinicopathologic entity". Am J Surg Pathol. 28 (7): 895–900. PMID 15223959. Unknown parameter |month= ignored (help)
  34. ↑ Perceau G, Derancourt C, Clavel C, Durlach A, Pluot M, Lardennois B, Bernard P (2003). "Lichen sclerosus is frequently present in penile squamous cell carcinomas but is not always associated with oncogenic human papillomavirus". Br J Dermatol. 148 (5): 934–8. PMID 12786823. Unknown parameter |month= ignored (help)
  35. ↑ Powell J, Robson A, Cranston D, Wojnarowska F, Turner R (2001). "High incidence of lichen sclerosus in patients with squamous cell carcinoma of the penis". Br J Dermatol. 145 (1): 85–9. PMID 11453912. Unknown parameter |month= ignored (help)
  36. ↑ Micali G, Nasca M, Innocenzi D (2001). "Lichen sclerosus of the glans is significantly associated with penile carcinoma". Sex Transm Infect. 77 (3): 226. PMID 11402247. Unknown parameter |month= ignored (help)
  37. ↑ Dayal S, Sahu P (2016). "Zoon balanitis: A comprehensive review". Indian J Sex Transm Dis. 37 (2): 129–138. doi:10.4103/0253-7184.192128. PMC 5111296. PMID 27890945.
  38. ↑ Neuhaus I, Skidmore R (1999). "Balanitis xerotica obliterans and its differential diagnosis". J Am Board Fam Pract. 12 (6): 473–6. PMID 10612365. Unknown parameter |month= ignored (help)
  39. ↑ Edwards SK, Bunker CB, Ziller F, van der Meijden WI (2014). "2013 European guideline for the management of balanoposthitis". Int J STD AIDS. 25 (9): 615–26. doi:10.1177/0956462414533099. PMID 24828553.
  40. ↑ Pastar Z, Rados J, Lipozencić J, Skerlev M, Loncarić D (2004). "Zoon plasma cell balanitis: an overview and role of histopathology". Acta Dermatovenerol Croat. 12 (4): 268–73. PMID 15588560.
  41. ↑ 41.0 41.1 Kumar B, Narang T, Dass Radotra B, Gupta S (2006). "Plasma cell balanitis: clinicopathologic study of 112 cases and treatment modalities". J Cutan Med Surg. 10 (1): 11–5. PMID 17241566.
  42. ↑ Adégbidi H, Atadokpèdé F, Dégboé B, Saka B, Akpadjan F, Yédomon H; et al. (2014). "[Zoon's balanitis in circumcised and HIV infected man, at Cotonou (Benin)]". Bull Soc Pathol Exot. 107 (3): 139–41. doi:10.1007/s13149-014-0359-4. PMID 24792459.
  43. ↑ Arzberger E, Komericki P, Ahlgrimm-Siess V, Massone C, Chubisov D, Hofmann-Wellenhof R (2013). "Differentiation between balanitis and carcinoma in situ using reflectance confocal microscopy". JAMA Dermatol. 149 (4): 440–5. doi:10.1001/jamadermatol.2013.2440. PMID 23325422.
  44. ↑ Errichetti E, Lacarrubba F, Micali G, Stinco G (2016). "Dermoscopy of Zoon's plasma cell balanitis". J Eur Acad Dermatol Venereol. 30 (12): e209–e210. doi:10.1111/jdv.13538. PMID 26670716.
  45. ↑ Edwards SK, Bunker CB, Ziller F, van der Meijden WI (2014). "2013 European guideline for the management of balanoposthitis". Int J STD AIDS. 25 (9): 615–26. doi:10.1177/0956462414533099. PMID 24828553.
  46. ↑ Clouston D, Hall A, Lawrentschuk N (2011). "Penile lichen sclerosus (balanitis xerotica obliterans)". BJU Int. 108 Suppl 2: 14–9. doi:10.1111/j.1464-410X.2011.10699.x. PMID 22085120.
  47. ↑ Dayal S, Sahu P (2016). "Zoon balanitis: A comprehensive review". Indian J Sex Transm Dis. 37 (2): 129–138. doi:10.4103/0253-7184.192128. PMC 5111296. PMID 27890945.

Template:WikiDoc Sources<section></section><section><section></section><section></section></section>

Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox:Balanitis_xerotica_obliterans&oldid=1285562"